Evidence map›Paper›PMID 19011666›Full record

ArticleBone marrow transplantation2009

Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI.

T E Druley, R Hayashi, D B Mansur, Q Jean Zhang, Y Barnes, K Trinkaus, S Witty, T Thomas, E E Klein, J F DiPersio and 2 more

Open access · greenAbstract read
In one paragraph

Article in Bone marrow transplantation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Article
  3. Article
  4. Review
  5. Perspectives toward oral mucositis prevention from parents and health care professionals in pediatric cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012
    Article
  6. Psychometric properties of the Oral Mucositis Daily Questionnaire for child self-report and importance of mucositis in children treated with chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

T E DruleyDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Bone Marrow Transplantation and Leukemia Section, Washington University School of Medicine, One Children's Place, Saint Louis, MO 63110, USA.
R Hayashi
D B Mansur
Q Jean Zhang
Y Barnes
K Trinkaus
S Witty
T Thomas
E E Klein
J F DiPersio
D Adkins
S Shenoy
Washington University in St. Louis · US

Funding

Training Program in Development HematologyT32HD007499 · NICHD · WASHINGTON UNIVERSITY · PI RUBIN, JOSHUA B · 1999 to 2019
$2.3M
NICHD NIH HHS T32 HD 007499NICHD NIH HHS T32 HD007499
6 · The paper itself

Abstract

Fractionated TBI (FTBI) followed by allogeneic hematopoietic SCT results in donor engraftment and improves survival in children with high-risk hematologic malignancies. However, acute toxicities (skin, lung and mucosa) are common after FTBI. Late complications include cataracts, endocrine dysfunction, sterility and impaired neurodevelopment. Instead of FTBI, we used low-dose single fraction TBI (550 cGy) with CY as transplant conditioning for pediatric hematologic malignancies. GVHD prophylaxis included CYA and short-course MTX; methylprednisolone was added for unrelated donor transplants. A total of 55 children in first (40%) or second remission and beyond (60%) underwent transplantation from BM (65%) or peripheral blood; 62% from unrelated donors; 22% were mismatched. Median follow-up was 18.5 months (1-68). Overall survival and disease-free survival at 1 year were 60 and 47%, respectively. Acute toxicities included grade 3-4 mucositis (18%), invasive infections (11%), multiorgan failure/shock (11%), hemolytic anemia (7%), veno-occlusive disease (4%) and renal failure (4%). TRM was 11% at 100 days. Non-relapse mortality was 6% thereafter. Graft rejection occurred in 2%. Three patients (5%) died of GVHD. The regimen was well tolerated even in heavily pretreated children and supported donor cell engraftment; long-term follow up is in progress.

Indexed as

AdolescentChildChild, PreschoolCombined Modality TherapyDisease-Free SurvivalFemaleGraft SurvivalGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansInfantMaleNeutrophilsTransplantation ChimeraTransplantation Conditioning

Identifiers

PMID19011666
PMCPMC2792985
OpenAlexW1995311732

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.